|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1001 PENNSYLVANIA AVENUE NW |
Address2 | SUITE 650N |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | Bridgewater |
State | NJ |
Zip Code | 08807 |
Country | USA |
|
5. Senate ID# 56838-12
|
||||||||
|
6. House ID# 351860000
|
TYPE OF REPORT | 8. Year | 2023 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Katie Oppenheim |
Date | 10/18/2023 8:50:57 AM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Issues related to Prescription to over-the-counter switch; issues related to influenza vaccines; issues related to 340B program; issues related to Respiratory Syncytial Virus (RSV); issues related to routine immunization rates; general issues related to Vaccines; issues related to Clinical Trial Diversity; general issues related to drug pricing; issues related to Out of Pocket (OOP) Cap; general issues related to Insulin pricing; issues related to HR 5376 "Inflation Reduction Act"; issues related to Additional Condition for Prescription Use (ACNU); issues related to Copay Accumulators; issues related to HR 3656 "Vaccine Improvement Act"; issues related to HR 830 "HELP Copay Act"; issues related to the reauthorization of "Pandemic and All-Hazards Preparedness Act" PAHPA; issues related to HR 1503 "Prescription Information Modernization Act of 2023"; general issues related to FDA; issues related to FDA Drug development; issues related to Pharmacy Benefit Managers (PBM); issues related to insurance design; general issues related to Pandemic Preparedness; issues related to Vaccine Injury Compensation Program (VICP); issues related to Pandemic and All-Hazards Preparedness Act Reauthorization (PAHPA); issues related to S.1542 "DRUG Act", issues related to S.1375 "HELP Copays Act"; issues related to S.1339 "PBM Reform Act"; issues related to Pharmacy Benefits Managers Reform; issues related to HR 3285 "Fairness for Patient Medications Act"; issues related to transplants; issues related to delinking; issues related to HR 2880 "Protecting Patients Against PBM Abuses Act"; issues related to RSV immunizations; issues related to INSULIN ACT; issues related to MDRP Proposed Rule; issues related to HR 4421 "Preparing for all Hazards and Pathogens Reauthorization Act"; issues related to Share the Savings with Seniors Act in HR 5376; issues related to HR 3008 "Drug Shortage Prevention Act of 2023"; Issues related to HR 4988 "Modern Authentication of Pharmaceuticals Act"; and issues related to HR 4881 to amend title XVIII of the Social Security Act to limit cost sharing for drugs under Medicare Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Amy |
Redl |
|
|
|
Katie |
Oppenheim |
|
|
|
Morgan |
Bradley-Jones |
|
|
|
Claire |
Brandewie |
|
|
|
Jennifer |
Dale |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to Medicare Negotiations; issues related to drug pricing negotiations; and issues related to 340B.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Oppenheim |
|
|
|
Jennifer |
Dale |
|
|
|
Amy |
Redl |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
Issues related to WTO Trips Waiver; issues related to Trade; and issues related to Importation.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Katie |
Oppenheim |
|
|
|
Morgan |
Bradley-Jones |
|
|
|
Claire |
Brandewie |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
General issues related to Taxes; issues relating to S.3087 "Vaccine Access Improvement Act"; issues related to tax credits; issues related to Vaccine Injury Compensation Program (VICP); and issues related to HR 3656 (117th) Vaccine Access Improvement Act.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Morgan |
Bradley-Jones |
|
|
|
Katie |
Oppenheim |
|
|
|
Claire |
Brandewie |
|
|
|
Jennifer |
Dale |
|
|
|
Amy |
Redl |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Issues related to Intellectual Property; and issues related to S.150 "Affordable Prescriptions for Patients Act".
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Claire |
Brandewie |
|
|
|
Katie |
Oppenheim |
|
|
|
Jennifer |
Dale |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
Issues related to drug pricing; issues related to vaccines; issues related to intellectual property; issues related to supply chain, and issues related to RSV.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Morgan |
Bradley-Jones |
|
|
|
Katie |
Oppenheim |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi US Services Inc is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit Sanofi US Services Inc., so too Sanofi SA, as the parent corporation, will benefit.
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |